The eukaryotic cell nucleus is a highly dynamic organelle. This is illustrated most dramatically during mitosis, when the nuclear envelope breaks down, the nuclear lamina dis assembles, chromosomes condense, and a microtubulebased spindle apparatus distributes sister chromatids to the dividing daughter cells. Many of these dramatic changes in nuclear architecture and microtubule organiz ation are controlled by phosphorylation and dephosphory lation events. Whereas the cardinal role of cyclindependent kinases (CDKs) in the regulation of mitosis is well established, there is now clear evidence for the requirement of additional mitotic protein kinases. Studies into the regulation of CDKs and other mitotic kinases have revealed that these enzymes undergo cell cycle dependent changes in subcellular distribution, suggesting that local ization may contribute to regulating their activities. This article describes some recent findings relating to the nucle ocytoplasmic translocation of CDK/cyclin complexes at the onset of mitosis. In addition, it summarizes recent infor mation on two novel human protein kinases which have been implicated in the control of mitotic progression. K ey w ords: n u cleo cy to p la sm ic traffick in g, m itosis, protein kinase
INTRODUCTION
Major transitions in the eukaryotic cell cycle are controlled by cyclin-dependent kinases (CDKs). These enzymes are composed of catalytic subunits structurally related to the cdc2/CDC28 gene products of fission and budding yeast, respectively, and they require the association of cyclin regula tory subunits for activity (Norbury and Nurse, 1992; Murray and Hunt, 1993; Nigg, 1993a,b) . Individual CDK/cyclin complexes are themselves controlled by multiple mechanisms, including the synthesis and destruction of cyclins, specific phosphorylation-déphosphorylation events, and the binding of inhibitory polypeptides (Sherr, 1994; Hunter and Pines, 1994; Morgan, 1995; Nigg, 1995) . Furthermore, different CDK/cyclin complexes and enzymes acting on these complexes localize to different subcellular compartments, sug gesting that spatial segregation may contribute to regulation. In other words, positive or negative regulators of CDK/cyclin activity could conceivably be brought into contact with their targets only at appropriate points in the cell cycle. In addition, precise spatial distributions may contribute to determining the availability of physiological substrates of CDK/cyclin complexes Hunter, 1991, 1994; Gallant and Nigg, 1992; Ookata et al., 1992; Maridor et al., 1993) . As an illus tration of this view, even the closely related mammalian cyclins B1 and B2 were recently shown to display different subcellular localizations during interphase (Jackman et al., 1995) . Human cyclin B1 was found to associate with microtubules, whereas cyclin B2 was concentrated in the Golgi area, suggesting an interaction with membraneous structures (Jackman et al., 1995) . Independently, a microtubule associa tion has also been reported for starfish cyclin B (Ookata et al., 1995) .
Although the crucial role of CDK/cyclin complexes in cell cycle control is well established, there is no doubt that other protein kinases also contribute to regulate many important aspects of cell cycle progression. This is illustrated particularly well by genetic analyses of mutants displaying cell cycle defects in various organisms. Examples include CDC7, CDC5 and CDC15 of Saccharomyces cerevisiae (Patterson et al., 1986; Schweitzer and Philippsen, 1991; Kitada et al., 1993) , chkl and cd cl6 of Schizosaccharomyces pombe (Walworth et al., 1993; Fankhauser et al., 1993) , NIMA of Aspergillus nidulans (Osmani et al., 1991) and polo of Drosophila melanogaster (Llamazares et al., 1991) . Considering the evo lutionary conservation of key cell cycle regulatory mechanisms in all eukaryotes, it is not surprising that candidate mammalian homologs of some of the above protein kinases, notably NIMA (Letwin et al., 1992; Schultz and Nigg, 1993; Schultz et al., 1994) and polo (Clay et al., 1993; Lake and Jelinek, 1993; Golsteyn et al., 1994; Hamanaka et al., 1994; Holtrich et al., 1994) have recently been isolated.
In this brief article, we describe experiments aimed at elu cidating spatial aspects of cell cycle control, focusing on the subcellular distribution of p34CDC2/cyclin B complexes. In addition, we summarize recent information obtained on the properties and localization of two novel human protein kinases, P lkl and Nek2, that are structurally distinct from CDKs and yet likely to play a role in cell cycle regulation.
MITOTIC CDK/CYCLIN COMPLEXES DISPLAY STRIKINGLY DIFFERENT SUBCELLULAR DISTRIBUTIONS
Entry into mitosis is accompanied by profound changes in cellular organization (King et al., 1994) . In higher eukaryotes, these include nuclear envelope breakdown and lamina disas sembly, fragmentation of endomembranes and arrest of vesicular traffic, chromosome condensation, centrosome sepa ration and reorganization of the microtubule network into a mitotic spindle. Most of these changes are thought to be triggered, either directly or indirectly, by the activation of the p34CDC2 protein kinase, the prototypic member of the ver tebrate CDK family (Nurse, 1990; Norbury and Nurse, 1992; Nigg, 1993a,b) . Vertebrate p34CDC2 interacts with at least four distinct cyclins, A, B l, B2 and B3 (Pines and Hunter, 1991; Gallant and Nigg, 1992, 1994) . However, these complexes display distinct subcellular localizations. CDK complexes with cyclins A and B3 accumulate in the nucleus as soon as they are formed (Girard et al., 1991; Pagano et al., 1992; Zindy et al., 1992; M aridor et al., 1993; Gallant and Nigg, 1994) . In contrast, complexes comprising cyclins B l and B2 are cyto plasmic throughout interphase, but human cyclin B l and chicken cyclin B2 then translocate to the nucleus at the onset of mitosis, just prior to nuclear envelope breakdown (Pines and Hunter, 1991; Gallant and Nigg, 1992) . Similar results have also been reported for starfish cyclin B (Ookata et al., 1992) , but curiously, no nuclear translocation was observed in a recent study on human cyclin B2 (Jackman et al., 1995) .
At present, we do not know what molecular mechanisms account for the abrupt nuclear translocation of certain B-type cyclins at the G2/M transition. Likewise, it is unknown how other cyclins with a constitutively nuclear localization enter the nucleus. In our laboratory, we have studied cyclins A and B3. These two cyclins are nuclear although they do not contain a typical nuclear localization signal (NLS) of either the mono or bipartite type (Dingwall and Laskey, 1991) . Interestingly, mutational analyses have revealed that the nuclear localization of both cyclins A and B3 correlates with their ability to form complexes with CDK partners (Maridor et al., 1993; Gallant and Nigg, 1994) . CDKs do not contain NLSs either, but one might argue that an unusual type of NLS might be generated by the interaction of CDKs with cyclins A or B3. Alternatively, the nuclear localization of cyclin/CDK complexes might require a third protein (Maridor et al., 1993) . In this context, it is intriguing that the nuclear localization of cyclin A mutants correlates not only with their ability to bind CDKs, but also their ability to form complexes with p i 07 (S. Dayan, M. Ewan and E. A. Nigg, unpublished results), a nuclear protein related to the retinoblastoma gene product pRb (Ewen et al., 1992; Faha et al., 1992) . These observations fall in line with results obtained by Peeper, 1993) , showing that recombinant cyclin A binds to p l0 7 only in the presence of CDK2. Furthermore, they raise the possibility that proteins such as p i 07 might be impli cated in targeting cyclin A/CDK2 complexes to the nucleus. However, p i 07 is by no means the only protein with which cyclin A/CDK2 complexes interact. Other candidate nuclear carriers include the pl07-related protein p i 30 (Hannon et al., 1993; Li et al., 1993; Cobrinik et al., 1993) , the CDK inhibitor p21 (Serrano et al., 1993) , p9CKS1 (Richardson et al., 1990) , or members of the E2F transcription factor family (Krek et al., 1994) .
ON THE NUCLEAR TRANSLOCATION OF CYCLIN B COMPLEXES
Although cyclin B/p34CDC2 complexes are too large to enter the nucleus by passive diffusion (Paine and Horowitz, 1980) , they move to the nucleus in very early prophase, at a time when the nuclear membrane appears still intact, suggesting that the nuclear accumulation of cyclin B/p34CDC2 complexes results from an active process. As discussed above for cyclin A, cyclin B/p34CDC2 complexes do not contain an obvious NLS and the participation of a third protein may therefore be required. The identity of this (hypothetical) carrier protein is unknown, although again p9CKS1 and p21 make for candidates, and there are also hints that isoforms of CDC25 phosphatase might perform a transport function (Galaktionov and Beach, 1991; Jessus and Beach, 1992; Zheng and Ruderman, 1993; Heald et al., 1993) .
It is presently unknown whether the putative third protein is bound to cyclin B/p34CDC2 at all times or only at the G2/M transition. According to one attractive model, cyclin B/p34CDC2 complexes might be retained in the cytoplasm through specific interactions with immobilizing structures. Such interactions might persist for the most part of interphase, but be broken at the G2/M transition. Support for this model stems from recent work by Pines and Hunter (1994) . These authors found that the N terminus of human cyclin B 1 contains a motif that is necessary and sufficient for cytoplasmic anchoring of cyclin A/B fusion proteins. As shown in Fig. 1 , such a motif may also be present in chicken cyclin B2. When a myc-tagged version of the N-terminal 141 residues of chicken cyclin B2 was transfected into HeLa cells, this protein was not uniformly distributed between nucleus and cytoplasm, but displayed a predominantly cytoplasmic localization. Con sidering the fact that nuclear pores allow diffusion of globular proteins below 40 kDa (Paine and Horowitz, 1980) , the observed cytoplasmic compartmentalization of this small protein (18 kDa) is consistent with the existence of a cyto plasmic anchor for the N terminus of cyclin B2.
The translocation of cyclin B/p34CDC2 complexes to the nucleus occurs at about the same time that p34CDC2 is activated through dephosphorylation of threonine 14 (T14) and tyrosine 15 (Y15; Krek and Nigg, 1991a) . To determine whether the dephosphorylation of T14/Y15 might constitute a trigger for the nuclear translocation of the cyclin B/p34CDC2 complex, we have mutated T14 to alanine (A) and Y15 to phenylalanine (F) and asked whether the ectopic expression of such a p34CDC2 mutant would cause the premature translocation of cyclin B. However, expression of such a double mutant is known to cause the premature onset of certain mitotic events, including nuclear envelope breakdown (Krek and Nigg, 1991b; Heald et al., 1993) . Hence, it was necessary to perform these experi ments with a catalytically inactive mutant of p34CDC2, i.e. a protein carrying not only the T14A/Y15F mutations, but also a mutation within the catalytic domain (lysine (K) 51 to arginine (R)). Overexpression of this triple mutant p34CDC2 protein did not detectably influence the cytoplasmic distribu tion of either co-transfected chicken cyclin B2 or endogenous human cyclin B 1 (data not shown). We did not show directly that the triple mutant p34CDC2 still binds to cyclin B, but note that both the T14A /Y I5F double mutant and the K51R mutant bind cyclins efficiently (Krek and Nigg, 1991b; Marcote et al., 1993) . The above results suggest that dephosphorylation of p34CDC2 per se does not cause nuclear translocation of the complex. However, they do not exclude the possibility that nuclear import of p34CDC2/cyclin B may be triggered by the concomitant activation of p34CDC2. Activated p34CDC2 might conceivably phosphorylate the retention domain within cyclin B (Jackman et al., 1995) , or alternatively, a cytoplasmic anchoring protein, and either event might cause the p34CDC2/cyclin B complex to dissociate from the anchoring structure. In support of this idea, studies on prophase-arrested starfish eggs suggest that activation of p34CDC2 precedes the nuclear uptake of the p34CDC2/cyclin B complex (O okataet al., 1992) . Furthermore, CDC25C, the enzyme thought to be responsible for the activation of p34CDC2, was reported to localize to the cytoplasm (Heald et al., 1993) . However, the subcellular distribution of CDC25 isoforms remains a contro versial issue (Millar et al., 1991; Girard et al., 1992) .
SPATIAL SEPARATION OF CAK AND p34CDC2/CYCLIN B
It has been firmly established that the activity of p34CDC2 depends not only on cyclin binding but also on phosphoryla tion of threonine 161 (T 161; Gould et al., 1991; Ducommun et al., 1991; Krek and Nigg. 1992; Solomon. 1993) . A kinase able to phosphorylate this critical residue has been purified from Xenopus and starfish oocytes (Fesquet et al., 1993; Solomon et al.. 1993; Poon et al., 1993) . Surprisingly, this kinase, termed CAK (for CDK-activating kinase), was found to be itself a complex between a CDK (CDK7; formerly called MO 15) and a cyclin (cyclin H; Fisher and Morgan, 1994; Miikela et al., 1994) . Subcellular localization studies showed CDK7/M OI5 to be nuclear at all times, except for mitosis (Tassan et al., 1994) . This begs the question of how nuclear CDK7 comes into contact with the cytoplasmic p34CDC2/cyclin B complex which is presumed to be one of its major substrates. Unless additional CAKs remain to be discovered, it is difficult to escape the conclusion that either p34c DC2 and/or CDK7 must cross the nuclear envelope. Considering that p34CDC2 is present in excess over cyclins, it is attractive to speculate that monomeric p34CDC2 might be phosphorylated by CAK within the nucleus, but then shuttle to the cytoplasm (Schmidt Zachmann et al., 1993) and be captured by cyclin B (Tassan et al., 1994) .
W HAT IS THE ROLE OF p34CDC2/CYCLIN B TRANSLOCATION TO THE NUCLEUS?
The physiological significance of the abrupt change in subcel lular localization of certain B-type cyclins is unknown. Although activation of p34CDC2 was reported to occur in the cytoplasm of starfish eggs (Ookata et al., 1992) , no definitive data have been obtained for somatic cells. If dephosphoryla tion of p34CDC2 were to occur in the nucleus of somatic cells, one could argue that p34CDC2/cyclin B complexes are excluded from the nucleus in order to prevent premature activation of p34CDC2. According to such a scenario, the nuclear transloca tion of the cyclin B/p34CDC2 complexes might be rate limiting for their activation, and thus for the onset of mitosis. To test this hypothesis, we have attached a classical NLS, derived from SV40 T-antigen (Kalderon et al., 1984) , to the N terminus of chicken cyclin B2. As illustrated in Fig. 2 , this NLS-cyclin B2 protein was still able to functionally interact with CDK subunits present in a rabbit reticulolysate. In this experiment, wild-type and NLS-cyclin B2 were translated in vitro. Then, cyclin/CDK complexes were isolated using p9CKS1 affinity beads, and assayed for histone H 1 kinase activity, as described previously (Maridor et al., 1993) . As shown in Fig. 2 , NLScyclin B2 was as efficient as wild-type cyclin B2 in activating endogenous reticulocyte CDKs (compare lanes 3 and 4) . No significant histone HI kinase activity was recovered from lysates in the absence of a translation product (lane 1) or after translation of the nucleolar protein No38, used for control (lane 2). As shown by transient transfection experiments and immunoprécipitation, NLS-cyclin B2 was also able to interact with CDKs in vivo (data not shown).
Next, we examined the physiological effects of expressing NLS-cyclin B2 in HeLa cells. NLS-cyclin B2 was localized to the nucleus (Fig. 3A) , indicating that the SV40 T antigenderived NLS acted in a dominant fashion over the putative cytoplasmic anchoring mechanism. However, the constitutive nuclear localization of a B-type cyclin did not induce cells to enter mitosis prematurely. At different times after transfection, HeLa cells expressing either wild-type cyclin B2 or NLScyclin B2 were identified by indirect immunofluorescence microscopy, and the percentage of mitotic cells was deter mined. As reported previously (Gallant and Nigg, 1992) , and confirmed in Fig. 3B , overexpression of wild-type cyclin B2 caused some accumulation of mitotic cells, presumably reflect ing a delay in mitotic progression due to saturation of the degradation machinery by excess cyclin B2. Very similar results were obtained also for NLS-cyclin B2 (Fig. 3B) . Although the time course of accumulation of mitotic cells varied between different experiments, the expression of NLScyclin B2 never increased the percentage of mitotic cells above that observed as a consequence of expressing wild-type cyclin B2. These results fall in line with a recent study by Pines and Hunter (1994) . When these authors deleted a putative cyto plasmic retention signal from the N terminus of human cyclin B l, they observed constitutive nuclear localization of the cyclin mutant, without obvious effects on cell cycle progres sion. Taken together, these data demonstrate that untimely entry of cyclin B2/p34CDC2 into the nucleus is not sufficient to trigger the initiation of mitosis, and they suggest that subcel lular compartmentalization of B-type cyclins is only one of , 1984) in fram e to the N term inus o f chicken cyclin B2 (G allant and N igg, 1992) .
T he resulting protein displays the N -term inal sequence M E O K L IS E E D L N M N F E A P K K K R K V E D PRN S-L H A A M R H , follow ed by the com plete sequence o f w ild-type chicken cyclin B2 (NLS underlined). W ild-type cyclin B2 (lane 3)
and N L S-cyclin B2 (lane 4) w ere produced by coupled in vitro transcription-translation in a rabbit reticulocyte lysate, using the T N T system (Progm ega C orp.). several control mechanisms to ensure appropriate timing of the onset of mitosis. This conclusion is consistent with data showing that CDC25 phosphatases are tightly regulated (Izumi et al., 1992; Izumi and Mailer, 1992; Hoffmann et al., 1993; Clarke et al., 1993; Strausfeld et al., 1994) .
Plk1 AND Nek2, TWO NOVEL HUMAN PROTEIN KINASES IMPLICATED IN THE REGULATION OF MITOTIC EVENTS
There is increasing evidence that CDKs are not the only protein kinases required for entry into and progression through mitosis (for references see Introduction). In our laboratory, we have recently focused on two novel human protein kinases termed Plkl (polo-like kinase 1) and Nek2 (NIMA related kinase 2), respectively. Both kinases were cloned by a PCR approach aimed at the isolation of cDNA fragments coding for potential human homologs of known yeast or invertebrate kinases for which genetic evidence suggested a role in cell cycle control (Schultz and Nigg, 1993) . Plkl is closely related to protein kinases of Drosophila and Saccharomyces cerevisiae, termed polo (Llamazares et al., 1991) and CDC5p (Kitada et al., 1993) , respectively. Sequence conservation among these three proteins is not limited to the N-terminal catalytic domain but extends throughout their Ctermini, suggesting that they may well represent functional homologs in their respective species. In support of this view, mutations in both Drosophila polo and S. cerevisiae CDC5 genes cause cells to arrest in late mitosis. A mitotic function is also suggested for the human P lkl: firstly, P lkl activity peaks during mitosis, and secondly, the Plkl protein displays a dynamic association with the mitotic spindle apparatus (Golsteyn et al., 1995) . During interphase, Plkl shows a pro nounced association with centrosomes, in addition to being diffusely distributed throughout the cell. This centrosome asso ciation persists into prometaphase, after the duplicated centro somes have moved apart and nucleated a mitotic spindle. However, as cells pass from metaphase to anaphase, Plkl shifts from the centrosome to overlapping half-spindles in the midzone between the separating chromosomes. Finally, as cells divide, P lk l is concentrated in the postmitotic bridges, close to the midbody (Golsteyn et al., 1995) . It remains to be determined whether Plkl is active at all these locations and, as yet, no substrates have been identified for polo-related kinases in any species.
The NIMA protein kinase has been identified as a mitotic regulator in the filamentous fungus Aspergillus nidulans (Osmani et al., 1991) . In the absence of NIMA function, cells arrest specifically in G2, whereas overexpression of NIMA causes cells to enter a premature mitotic state (Osmani et al., 1988) . Recent studies show that NIMA functions downstream of p34CDC2/cyclin B (Ye et al., 1995) , and that destruction of NIMA is required for exit from mitosis (Pu and Osmani, 1995) . Although no physiological substrates of NIMA have so far been identified, there is evidence to suggest that the NIMA kinase may promote chromosome condensation (O 'Connell et al., 1994; Ye et al., 1995) . NIMA-related protein kinases have been identified in S. cerevisiae (Jones and Rosamond, 1990; Schweitzer and Philippsen, 1992) 2) or a Nek2-recombinant (lanes 3-8) baculovirus. At the indicated times after infection, crude whole cell lysates were prepared and separated by SDS-PAGE before immunoblotting with the Nek2-specific affinity-purified R31 antibody. Molecular masses (kDa) are shown on the left and the position of the Nek2 protein is indicated on the right.
and Schultz et al., 1994; Levedakou et al., 1994) . By structural criteria, Nek2 is the closest known mammalian relative of Aspergillus NIMA. However, sequence similarity between the two kinases is limited to the catalytic domain, and there are no definitive data to decide whether Nek2 represents a functional homolog of NIMA. Biochemical studies on Nek2 had originally been hampered by the difficulty to detect kinase activity associated with Nek2 immunoprecipitates . To overcome this obstacle, we have now expressed human Nek2 from a recombinant baculovirus. Fig. 4 shows a time course of expression of human Nek2 in Sf9 insect cells. As determined by immunoblotting, expression o f the 46 kDa Nek2 protein could first be detected at about 18 hours after infection, and maximal levels were reached by 36-48 hours. Following immunoprécipitation of Nek2 from infected Sf9 cells, specific kinase activity could be detected, using casein as an exogenous substrate (Fry et al., 1995) . Casein was chosen as an in vitro substrate since this protein is a preferred substrate of Aspergillus NIMA (Lu et al., 1994) . To further compare the substrate specificity of human Nek2 with that of NIMA, we tested a number of widely used protein kinase substrates for their ability to be phosphorylated in vitro by immunoprecipitated recombinant Nek2 (Fig. 5) . Myelin basic protein (MPB) and microtubule-associated protein 2 (MAP2) were strongly phosphorylated, similar to (3-casein. Phosvitin and histone HI were phosphorylated moderately, but enolase, a frequently used substrate for tyrosine kinases, was not phosphoryated at all. In fact, Nek2 phosphorylated exclusively serine and/or threonine residues (Fig. 5C) . None of the above proteins was phosphorylated by a catalytically inactive Nek2 mutant protein prepared under identical conditions, attesting to the specificity of the observed reactions (data not shown).
Using optimized assay conditions, we have also been able to detect Nek2 activity after immunoprécipitation of this kinase from HeLa cells. Cell cycle synchronization experiments revealed that Nek2 protein expression as well as kinase activity are cell cycle regulated, being low in G t, but high in S and G2 phase of the cell cycle (Fry et al., 1995) . These results are con sistent with the possibility that Nek2 and NIMA may be func tionally related, but a more definitive assessment of the relationship between these kinases may have to await the iden tification of their physiological substrates.
Preliminary experiments suggest that Nek2 function may also be modulated through changes in subcellular localization. Transfection of untagged or myc-tagged versions of the wild type Nek2 kinase into cultured human cells shows that Nek2 is present exclusively in the cytoplasm of some cells, but in the nucleus of others (A. Fry, S. J. Schultz and E. A. Nigg, unpub lished results) . This is reminiscent of observations discussed above for p34CDC2/cyclin B, and raises the possibility that the nucleocytoplasmic distribution of Nek2 may vary with the cell cycle.
To gain further information about the functions of Nek2 and P lkl, we are currently microinjecting antibodies against these proteins into cells. Furthermore, the yeast two-hybrid system is being used to search for interacting proteins. We hope that these studies will contribute to elucidate the functions of these novel human protein kinases during cell cycle progression. 
